Cost-effectiveness analysis of second-line medical therapies in acromegaly: a real-life study

IntroductionAcromegaly is an uncommon disease with important comorbidity and economic cost. Although the pharmacological cost of second-line treatment for refractory acromegaly has been theoretically analyzed, real-life studies are needed.ObjectivesTo assess the use of pasireotide and pegvisomant in...

Full description

Bibliographic Details

Published in:	Frontiers in Endocrinology
Main Authors:	Eva Venegas Moreno, Andrés Jiménez-Sánchez, Pablo Remón-Ruiz, Elena Dios, Jaime Perea Cortés, Celia Hernández-Reina, David A. Cano, Alfonso Soto Moreno
Format:	Article
Language:	English
Published:	Frontiers Media S.A. 2025-04-01
Subjects:	acromegaly pasireotide pegvisomant cost analysis radiotherapy
Online Access:	https://www.frontiersin.org/articles/10.3389/fendo.2025.1573721/full